<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942730</url>
  </required_header>
  <id_info>
    <org_study_id>06/21-n</org_study_id>
    <nct_id>NCT04942730</nct_id>
  </id_info>
  <brief_title>Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)</brief_title>
  <acronym>FluBuBe</acronym>
  <official_title>Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and&#xD;
      graft-versus-host disease prophylaxis is associated with high frequency of primary and&#xD;
      secondary graft failure. Different technologies of with replete or depleted graft are&#xD;
      associated with 10-20% of graft failures. Fludarabine and busulfan conditioning is the most&#xD;
      commonly used approach for a variety of disease. Furthermore combination of fludarabine and&#xD;
      bendamustine was sufficient to facilitate engraftment in patients with chronic lymphocytic&#xD;
      leukemia and lymphomas. The aim of the study is to evaluate whether addition of bendamustine&#xD;
      to fladarabine and busulfan conditioning reduces the risk of primary graft failure after&#xD;
      haploidentical allograft.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Incidence of primary and secondary graft failure</measure>
    <time_frame>100 days</time_frame>
    <description>Proportion of patients with primary and secondary graft failure defined by the absence of donor chimerism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Incidence of HSCT-associated adverse events (safety and toxicity)</measure>
    <time_frame>125 days</time_frame>
    <description>Toxicity assessment is based on NCI CTC AE 5.0 grades. Veno-occlusive disease incidence and severity assessment is based on EBMT criteria 2016. Transplant-associated microangiopathy incidence assessment is based on Cho et al. criteria. All toxicity measurements will be aggregated as severity scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence</measure>
    <time_frame>[ Time Frame: 100 days ] [ Designated as safety issue: Yes ]</time_frame>
    <description>Proportion of patients, requiring systemic treatment for bacterial, viral and fungal disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Incidence of acute GVHD grade II-IV</measure>
    <time_frame>125 days</time_frame>
    <description>Cumulative incidence of patients with acute GVHD II-IV grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Incidence of moderate and severe chronic GVHD</measure>
    <time_frame>365 days</time_frame>
    <description>Cumulative incidence of patients with moderate and severe chronic GVHD according to NIH 2015 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Non-relapse mortality analysis</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of patients with mortality without hematological relapse of malignancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Overall survival analysis</measure>
    <time_frame>2 years</time_frame>
    <description>Kaplan-Meier estimate of death from all causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Event-free survival analysis</measure>
    <time_frame>2 years</time_frame>
    <description>Kaplan-Meier estimate of death or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Relapse rate analysis</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of patients with relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia, Acute Lymphoblastic</condition>
  <condition>Myeloid Leukemia, Acute</condition>
  <condition>Biphenotypic Acute Leukemia</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>FluBuBe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 130 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT</description>
    <arm_group_label>FluBuBe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine Hydrochloride</intervention_name>
    <description>130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT</description>
    <arm_group_label>FluBuBe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>1 mg/kg po qid x 3 days, Days -5 through -3</description>
    <arm_group_label>FluBuBe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg iv x 2 days, Days +3 through +4</description>
    <arm_group_label>FluBuBe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35</description>
    <arm_group_label>FluBuBe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus 5Mg Cap</intervention_name>
    <description>0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.</description>
    <arm_group_label>FluBuBe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have an indication for allogeneic hematopoietic stem cell&#xD;
             transplantation with myeloablative conditioning for malignant disease&#xD;
&#xD;
          -  Patients with 5-9/10 HLA-matched related donor available. The donor and recipient must&#xD;
             be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and&#xD;
             HLA-DQB1.&#xD;
&#xD;
          -  Peripheral blood stem cells or bone marrow as a graft source&#xD;
&#xD;
          -  No second malignancies requiring treatment&#xD;
&#xD;
          -  No severe concurrent illness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Titer of anti-HLA antibodies â‰¥ 5000 at the time of inclusion&#xD;
&#xD;
          -  Moderate or severe cardiac dysfunction, left ventricular ejection fraction &lt;50%&#xD;
&#xD;
          -  Moderate or severe decrease in pulmonary function, FEV1 &lt;70% or DLCO&lt;70% of predicted&#xD;
&#xD;
          -  Respiratory distress &gt;grade I&#xD;
&#xD;
          -  Severe organ dysfunction: AST or ALT &gt;5 upper normal limits, bilirubin &gt;1.5 upper&#xD;
             normal limits, creatinine &gt;2 upper normal limits&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min&#xD;
&#xD;
          -  Uncontrolled bacterial or fungal infection at the time of enrollment&#xD;
&#xD;
          -  Requirement for vasopressor support at the time of enrollment&#xD;
&#xD;
          -  Karnofsky index &lt;30%&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Somatic or psychiatric disorder making the patient unable to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ivan S Moiseev, MD, Prof.</last_name>
    <phone>+79217961951</phone>
    <email>moisiv@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandr D Kulagin, MD, Prof.</last_name>
    <phone>+78123386265</phone>
    <email>bmt-director@1spbgmu.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RM Gorbacheva Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Moiseev</last_name>
      <phone>+79217961951</phone>
      <email>moisiv@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Alexandr Kulagin</last_name>
      <phone>+78123386265</phone>
      <email>bmt-director@1spbgmu.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Petersburg State Pavlov Medical University</investigator_affiliation>
    <investigator_full_name>Ivan S Moiseev</investigator_full_name>
    <investigator_title>Vice-pdirector for science RM Gorbacheva Institute</investigator_title>
  </responsible_party>
  <keyword>Fludarabine</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Myeloablative Agonists</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Antineoplastic Agents, Alkylating</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Request for sharing data with the study plan for the data will be evaluated under common conditions by Pavlov University Ethical Committee.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

